Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A site-change that invalidates stability claims put CMC comparability package for a site change in front of pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate. This Pharma & Life Sciences / Pharmacovigilance close is to drop a secondary from CMC comparability package for a site change, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Pharmacovigilance medical reviewer can defend Proceed under protocol from CMC comparability package for a site change after a site-change that invalidates stability claims in a Pharma & Life Sciences challenge. 2. Pharmacovigilance medical reviewer cannot defend Proceed under protocol from CMC comparability package for a site change; Pause the pathway is what the extract actually supports after a site-change that invalidates stability claims. 3. A site-change that invalidates stability claims never reached the population in CMC comparability package for a site change — reopen intake, do not close to drop a secondary. 4. Two facts in CMC comparability package for a site change after a site-change that invalidates stability claims conflict for pharmacovigilance medical reviewer; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether CMC comparability package for a site change supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 4. For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a site-change that invalidates stability claims). The follow-on Pharmacovigilance action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in CMC comparability package for a site change, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Missing page in CMC comparability package for a site change after a site-change that invalidates stability claims, if any - Regulatory or exam hook Pharmacovigilance would cite